A legal clash has erupted between pharmaceutical company Eli Lilly and activist RFK Jr. over regulatory approval for Retatrutide, a weight-loss drug. The dispute centers on whether the U.S. Food and Drug Administration should require long-term safety data before greenlighting the treatment. Critics argue the drug’s fast-tracked development poses risks, while supporters claim it could offer a breakthrough for obesity treatment. The outcome could set a precedent for how emerging medications are evaluated under current health policies.
It’s Eli Lilly vs. RFK Jr. in a battle over the rules around Retatrutide.
